WO2005053711A1 - Inducteur de l'interferon gamma - Google Patents

Inducteur de l'interferon gamma Download PDF

Info

Publication number
WO2005053711A1
WO2005053711A1 PCT/RU2004/000470 RU2004000470W WO2005053711A1 WO 2005053711 A1 WO2005053711 A1 WO 2005053711A1 RU 2004000470 W RU2004000470 W RU 2004000470W WO 2005053711 A1 WO2005053711 A1 WO 2005053711A1
Authority
WO
WIPO (PCT)
Prior art keywords
gamma
niglizine
interferon
concentration
mice
Prior art date
Application number
PCT/RU2004/000470
Other languages
English (en)
Russian (ru)
Inventor
Andrei Georgievich Pokrovsky
Nina Vladimirovna Fedyuk
Sandzhar Mukhudinovich Abdullaev
Lidia Ashrafovna Baltina
Genrikh Aleksandrovich Tolstikov
Original Assignee
Andrei Georgievich Pokrovsky
Nina Vladimirovna Fedyuk
Abdullaev Sandzhar Mukhudinovi
Lidia Ashrafovna Baltina
Tolstikov Genrikh Aleksandrovi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrei Georgievich Pokrovsky, Nina Vladimirovna Fedyuk, Abdullaev Sandzhar Mukhudinovi, Lidia Ashrafovna Baltina, Tolstikov Genrikh Aleksandrovi filed Critical Andrei Georgievich Pokrovsky
Publication of WO2005053711A1 publication Critical patent/WO2005053711A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the gamma interface is the markers.
  • the immune-stimulating effect for gamma-interactions it is a complex, antiperspirant, non-invasive, and non-invasive device.
  • the 20 sources of gamma-ray are the 1st type cells ( ⁇ ), cytotoxic lymphocytes, and normal silent cells.
  • the clinical practice of gamma-ray therapy is used in patients with AIDS and in the treatment of acute infections. It is shown that the introduction of the gamma-interface improves the survival rate of patients with
  • the product of the invention is the detection of new properties of the treatment of niglizine, which is more important for the production of gamma-virus.
  • the non-medical result is achieved by the use of a derivative of glycyrrhizic acid (niglizine) - a penta-narcotic-diabetes mellitus P ⁇ imeneiie niglizina ( ⁇ en ⁇ a-o-ni ⁇ ina ⁇ glitsi ⁇ izin ⁇ v ⁇ y ⁇ isl ⁇ y) in ⁇ aches ⁇ ve indu ⁇ a in ⁇ e ⁇ e ⁇ na in is ⁇ chni ⁇ a ⁇ ⁇ a ⁇ en ⁇ n ⁇ y and nauchn ⁇ - ⁇ e ⁇ niches ⁇ y in ⁇ matsii not ⁇ isan, sled ⁇ va ⁇ eln ⁇ , m ⁇ zhn ⁇ 0 sdela ⁇ vyv ⁇ d o s ⁇ ve ⁇ s ⁇ vii ⁇ e ⁇ niches ⁇ g
  • mice dissolve niglizine (penta-nitrate and glycyrrhizic acid) in ⁇ , and then there is no waste.
  • Group ⁇ 3 mice enter 5 niglizine solution with a volume of 0.5 ml with a concentration of 400 ⁇ g / ml, 40 ⁇ l / ml and 4 ⁇ g / ml internally, after 12, 24 and 48 hours, the spleen is removed from the plant. In terms of quality, mice enter 4% of children.
  • CONTROL - a cellular environment 0.167 mcg / ml; 1.0 mcg / ml; 6.0 mcg / ml - niglizine concentration; Beneficial areas: I - ionomycin with ⁇ ; II - mono-local anti-SZZ antibodies.
  • ⁇ a ⁇ ig. 2 shows the dependence of gamma numbers
  • the mixture is diluted with a free buffer at a ratio of 1: 1 and the diluted buffer is applied to the disposable medium. Separation is made by centrifugation at 1500 rpm for 40 minutes. In the case of a power supply, they are prepared, dispersed in 3 ml of an optional buffer and washed twice with a centrifuge for 5 minutes at 1500 rpm. Dry washing in a medium ⁇ 1640 in a volume of 2 ml. After a third wash, the mononuclear cells are suspended in 1 ml of medium. 2.
  • ⁇ iglizin penenta-o-niacin-free glycyrrhizic acid grows in ⁇ , and then the quick-fix buffer () 5 worthwhile accents.
  • Royal-12-Miristat-13-acetate ( ⁇ ) and ionomycin, and, therefore, multiple anti-SDZ antibodies are used as a positive partner.
  • the division of the gamma inter- face is provided by the serial mono-multiplexer ⁇ 8 ⁇ .
  • the collection of mouse anti-gamma-interface is a multi-channel antenna located in the external
  • the method of using live animals in the experiment is an experiment using linear mice of the L / C line with a mass of 18 - 20 g of free food, only 36 in total.
  • niglizine is dissolved in ⁇ , and then, in turn, the Federal Security Service makes it possible to obtain an accent.
  • Groups of mice and mice inject a niglizine solution with a volume of 0.5 ml with a concentration of 400 mcg / ml; 40 mcg / ml and 4 mcg / ml internally, after 12, 24 and 48 hours, they take away the spleens and evaluate the gamma-interactions.
  • Fort Quality control a niglizine solution with a volume of 0.5 ml with a concentration of 400 mcg / ml; 40 mcg / ml and 4 mcg / ml internally, after 12, 24 and 48 hours, they take away the spleens and evaluate the gamma-interactions
  • mice were administered 4% of the disinfectant. 5.
  • ⁇ e ⁇ di ⁇ a ⁇ edeleniya du ⁇ tsii gamma in ⁇ e ⁇ e ⁇ na s ⁇ len ⁇ tsi ⁇ ami mice me ⁇ d ⁇ m ⁇ Y8 ⁇ S ⁇ us ⁇ ya 12, 24 and 48 hours mice ⁇ sle ine ⁇ tsii niglizina ume ⁇ schvlyayu ⁇ me ⁇ d ⁇ m tse ⁇ vi ⁇ aln ⁇ y ⁇ ansl ⁇ atsii and ase ⁇ iches ⁇ i ⁇ usl ⁇ viya ⁇ 0 ⁇ izv ⁇ dya ⁇ izya ⁇ ie selezen ⁇ .
  • the spleen passes through the metal system, it is suspended in the medium ⁇ 1640, after it is washed out once in the same medium, each time takes 1500/10 minutes.
  • the anti-mouse gamma-interferon binding mono-5 antibodies at a concentration of 5 ⁇ g / ml in a volume of 100 ⁇ l are scrubbed on a plate with a pulp-free bottom.
  • unconnected sites block 150 mcl / well of solution ⁇ 1640 with 10% fetal delivery. After rinsing in the wells, add a suspension of the membrane with a volume of 200 microliters with a concentration of cells of 1 million / ml.
  • niglizine in the range of 0.167 - 6 mcg / ml is significantly more accessible ( ⁇ ⁇ 0.05), which increases the gamma-internametry.
  • a maximum stimulation of 25 is observed at a level of niglizine equal to 1 mg / ml.
  • a twofold increase in the number of spots from 1.2 to 5.5 times).
  • niglizine The effect of niglizine on the production of gamma-interferon with the erythrocytes of mice ⁇ ⁇ due to the results of the experiment ⁇ ⁇ , shown on the mouse, is shown in ⁇ . 1.
  • An increase in the gamma-interferon sequence with the fascicles was observed only after 48 h after a single administration of niglizine in doses of 1 and 10 mcg / kg (phig. 3). After 12 and 24 hours after a single introduction 5 niglizine in the studied doses, the number of shared points is not distinguished from the counter.
  • niglisin increases the gamma-interactions, which means that it is inaccessible for use.
  • INDUSTRIAL APPLICABILITY The invention may be used in pharmaceuticals and scientific research.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention relève des domaines de la médecine et de la pharmacologie et concerne plus précisément des préparations qui sont utilisées comme inducteurs de l'interféron gamma et en particulier des dérivés de l'acide glycyrrhizique (niglizine) influant sur la sécrétion d'interféron gamma dans des conditions in vitro et in vivo. Lorsqu'on utilise la niglizine (penta-O-nicotinate d'acide glycyrrhizique) à une concentration comprise entre 0,167 et 6 νg/ml, on observe une augmentation statistiquement établie de la sécrétion d'interféron gamma par les mononucléaires du sang.
PCT/RU2004/000470 2003-12-01 2004-11-29 Inducteur de l'interferon gamma WO2005053711A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2003134868/15A RU2254861C1 (ru) 2003-12-01 2003-12-01 Индуктор гамма-интерферона
RU2003134868 2003-12-01

Publications (1)

Publication Number Publication Date
WO2005053711A1 true WO2005053711A1 (fr) 2005-06-16

Family

ID=34651600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2004/000470 WO2005053711A1 (fr) 2003-12-01 2004-11-29 Inducteur de l'interferon gamma

Country Status (2)

Country Link
RU (1) RU2254861C1 (fr)
WO (1) WO2005053711A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140345A1 (fr) * 2007-05-16 2008-11-20 Zakritoe Aktsionernoe Obschestvo 'sibpharmakon' Di- et/ou trinicotinates d'acide glycyrrhizique et inhibiteur de propagation du virus de l'immunodéficience humaine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1499901A1 (ru) * 1987-12-21 1991-04-30 Институт химии Башкирского научного центра Уральского отделения АН СССР N-Хинолин-6-иламид пентаацетилглицирризиновой кислоты, про вл ющий противовоспалительную и противо звенную активность
SU1626663A1 (ru) * 1989-07-31 1994-03-15 Институт химии Башкирского научного центра Уральского отделения АН СССР КОРИЧНЫЙ ЭФИР β -ГЛИЦИРРИЗИНОВОЙ КИСЛОТЫ, ПРОЯВЛЯЮЩИЙ ПРОТИВОВОСПАЛИТЕЛЬНУЮ И ПРОТИВОЯЗВЕННУЮ АКТИВНОСТИ
RU2073009C1 (ru) * 1992-06-15 1997-02-10 Институт органической химии Уральского научного центра РАН Способ получения пента-о-никотината глицирризиновой кислоты
US6383525B1 (en) * 2000-12-14 2002-05-07 Globoasia L.L.C. Herbal compositions for treating immunological disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1499901A1 (ru) * 1987-12-21 1991-04-30 Институт химии Башкирского научного центра Уральского отделения АН СССР N-Хинолин-6-иламид пентаацетилглицирризиновой кислоты, про вл ющий противовоспалительную и противо звенную активность
SU1626663A1 (ru) * 1989-07-31 1994-03-15 Институт химии Башкирского научного центра Уральского отделения АН СССР КОРИЧНЫЙ ЭФИР β -ГЛИЦИРРИЗИНОВОЙ КИСЛОТЫ, ПРОЯВЛЯЮЩИЙ ПРОТИВОВОСПАЛИТЕЛЬНУЮ И ПРОТИВОЯЗВЕННУЮ АКТИВНОСТИ
RU2073009C1 (ru) * 1992-06-15 1997-02-10 Институт органической химии Уральского научного центра РАН Способ получения пента-о-никотината глицирризиновой кислоты
US6383525B1 (en) * 2000-12-14 2002-05-07 Globoasia L.L.C. Herbal compositions for treating immunological disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALITINA L. ET AL.: "Sposob polucheniya glitsirrizinovoi kistoly is glitsirama. Farmakologicheskie svoistva", KHIMIKO-FARMATSEVTICHESKY ZHURNAL, vol. 35, no. 1, 2001, PUBLISHING HOUSE FOLIUM, pages 38 - 41 *
UTSUNOMIYA T. ET AL.: "Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus", ANTIMICROB AGENTS CHEMOTHER., vol. 41, no. 3, March 1997 (1997-03-01), pages 551 - 556 *

Also Published As

Publication number Publication date
RU2254861C1 (ru) 2005-06-27

Similar Documents

Publication Publication Date Title
Haneji et al. Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells
Ralph et al. Pharmacokinetics of metronidazole as determined by bioassay
Davies et al. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis
Moskowitz et al. Stimulation by growth hormone and dexamethasone of labeled cyclic adenosine 3', 5'-monophosphate accumulation by white fat cells
Kim et al. Extracellular vesicles derived from the periodontal pathogen Filifactor alocis induce systemic bone loss through Toll‐like receptor 2
WO2012061537A2 (fr) Méthodes de traitement de troubles capillaires
Caballero et al. Endogenous osteopontin induces myocardial CCL5 and MMP-2 activation that contributes to inflammation and cardiac remodeling in a mouse model of chronic Chagas heart disease
US6180612B1 (en) Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
McColm et al. Evaluation of a range of antimicrobial agents against the parasitic protozoa, Plasmodium falciparum, Babesia rodhaini and Theileria parva in vitro
Hevesy et al. Phosphorus exchange in yeast
Philips et al. Physiologic disposition and intracellular localization of isometamidium
Das et al. Rapid diagnosis of Campylobacter pyloridis infection.
GARSON et al. The 45, XO, Ph 1 subgroup of chronic granulocytic leukaemia
Balbi et al. Psychotropic drugs: evaluation of mutagenic effect
WO2005053711A1 (fr) Inducteur de l'interferon gamma
Karker Method for estimation of serum adenosine deaminase
Riegel Blood glucose in crayfishes in relation to moult and handling
Maxson et al. Albumin and Australian frogs: molecular data a challenge to speciation model
US20230009902A1 (en) Treatment of a disease or condition in a tissue orginating from the endoderm
Brabbs et al. Isolation and characterization of bleomycin-resistant clones of CHO cells
KR100464876B1 (ko) 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
Stemp et al. In vitro and in vivo cytogenetic studies of three β-lactam antibiotics (penicillin VK, ampicillin and carbenicillin)
Moraczewski et al. Distribution and rate of metabolism of phosphorus compounds in Trypanosoma equiperdum
Hanin et al. Acetylcholine and choline in human plasma and red blood cells: a gas chromatograph mass spectrometric evaluation
Debbia et al. In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 04808980

Country of ref document: EP

Kind code of ref document: A1